The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback